We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever.

Steve Elms Biography and Net Worth

Director of ADMA Biologics

Mr. Elms has been a director of the Company since 2007 and is the Company’s Chairman of the Board and a member of the Company’s Governance and Nominations Committee. Mr. Elms serves as a Managing Partner at Aisling Capital, which he joined in 2000. Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist. During his five years at Hambrecht & Quist, Mr. Elms was involved in over 60 financing and merger and acquisition transactions, helping clients raise in excess of $3.3 billion in capital. Prior to joining Hambrecht & Quist, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms currently serves on the board of directors of Zosano Pharma Corp. (Nasdaq: ZSAN) and previously served on the board of directors of Loxo Oncology, Inc. (Nasdaq: LOXO), Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Pernix Therapeutics Holdings, Inc. (OTCMKTS: PTXTQ) within the past five years. Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from Kellogg Graduate School of Management at Northwestern University. Mr. Elms was chosen to serve on the Board because of his valuable experience in the investment banking industry, particularly with respect to strategic and financing transactions.

What is Steve Elms' net worth?: The estimated net worth of Steve Elms is at least $44.00 million as of March 18th, 2024. Mr. Elms owns 2,527,500 shares of ADMA Biologics stock worth more than $44,003,775 as of December 25th. This net worth evaluation does not reflect any other investments that Mr. Elms may own. Learn More about Steve Elms' net worth.
How do I contact Steve Elms?: The corporate mailing address for Mr. Elms and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Steve Elms' contact information.
Has Steve Elms been buying or selling shares of ADMA Biologics?: Steve Elms has not been actively trading shares of ADMA Biologics in the last ninety days. Most recently, Steve Elms sold 49,887 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $6.01, for a transaction totalling $299,820.87. Following the completion of the sale, the director now directly owns 2,527,500 shares of the company's stock, valued at $15,190,275. Learn More on Steve Elms' trading history.
Who are ADMA Biologics' active insiders?: ADMA Biologics' insider roster includes Steve Elms (Director), Bryant Fong (Director), Adam Grossman (Co-Founder, President, CEO & Director), Jerrold Grossman (Director), Lawrence Guiheen (Director), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.
Are insiders buying or selling shares of ADMA Biologics?: During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 1,221,795 shares worth more than $13,540,539.83. The most recent insider tranaction occured on November, 22nd when CFO Brad L Tade sold 15,000 shares worth more than $317,250.00. Insiders at ADMA Biologics own 3.7% of the company. Learn More about insider trades at ADMA Biologics.
Information on this page was last updated on 11/22/2024.

Steve Elms Insider Trading History at ADMA Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Sell	49,887	$6.01	$299,820.87	2,527,500
3/15/2024	Sell	183,008	$6.01	$1,099,878.08	2,577,387
3/13/2024	Sell	407,000	$6.21	$2,527,470.00	3,208,671

Steve Elms Buying and Selling Activity at ADMA Biologics

ADMA Biologics Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Today's Range

Now: $17.54

$17.20

$17.54

50 Day Range

MA: $18.99

$15.62

$22.62

2 Week Range

Now: $17.54

$4.36

$23.64

Volume

156,144 shs

Average Volume

3,543,720 shs

Market Capitalization

$4.15 billion

P/E Ratio

62.64

Dividend Yield

N/A

Beta

0.7

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.